REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

26/09/2016 16:00

RNS Number : 8429K
AstraZeneca PLC
26 September 2016
26 September 2016 16:00
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.
The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.
One ordinary share equals two ADSs.
After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.
For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Sean Bohen
2 
Reason for the notification 
a) 
Position/status 
Executive Vice-President, Global Medicines Development and Chief Medical Officer
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
Not applicable
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
b) 
Nature of the transaction 
Acquisition of AstraZeneca American Depositary Shares pursuant to the vesting of an award under the AstraZeneca Restricted Share Plan
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
$33.97
12,385
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
26 September 2016
f) 
Place of the transaction 
New York
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 
CONTACTS
Media Enquiries
Neil Burrows
UK/Global
+44 203 749 5637
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


UK


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Nick Stone
Respiratory & Autoimmunity
+44 203 749 5716
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
Infection & Neuroscience
+44 203 749 5711
US


Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Mitchell Chan
Oncology
+1 240 477 3771
Toll-free

+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUNUORNOAKUAR